日本无限资源_福禄影院午夜伦_美国av毛片_亚洲自拍在线观看_激情亚洲一区国产精品_999久久久久

Chinese Alzheimer's drug to undergo global clinical trials

Source: Xinhua| 2020-01-04 18:58:21|Editor: zh
Video PlayerClose

BEIJING, Jan. 4 (Xinhua) -- An innovative Chinese Alzheimer's drug that hit the domestic market last week will go through clinical trials on 2,000 patients overseas in 2020.

The orally administered drug GV-971 will be tested in 200 clinical centers in North America, the European Union, Eastern Europe, Asia Pacific and other places, according to Green Valley Pharmaceutical Co., Ltd, one of the drug's co-developers.

The company said it plans to complete the global clinical trials in 2024 and submit the New Drug Application to the U.S. Food and Drug Administration and European Medicines Agency in 2025.

GV-971 was jointly developed by the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences (CAS), Ocean University of China and Green Valley, after a 22-year study.

The results of the mechanism of action study were published in the international journal Cell Research in September 2019, saying that the drug, extracted from brown algae, works by modifying gut bacteria to ultimately reduce brain inflammation in mice that were genetically engineered to have the disease.

It was approved to market last November by China's National Medical Products Administration, which said the GV-971 "can improve cognition in patients with mild to moderate Alzheimer's disease (AD)."

According to researchers, apart from animal experiments, more than 1,100 Chinese AD patients participated in clinical trials before the drug hit the market. In the last test, a total of 818 participants from 34 leading hospitals in China took 450 mg GV-971 orally twice a day for a treatment period of nine months, which proved safe and effective in improving cognition.

"Because of its effectiveness on Chinese patients, we expect this drug to benefit more people in the rest of the world," said Lyu Songtao, chairman of the Shanghai-based pharmaceutical company.

At least 50 million people worldwide have dementia and AD is the root cause behind 60 percent to 70 percent of the cases, according to the World Health Organization.

AD is an irreversible, progressive brain disorder that slowly destroys memory, thinking skills and the ability to carry out simple tasks.

China currently has about 10 million AD patients and the number is expected to increase to 40 million by 2050, more than the population of Canada, according to China Association of Gerontology and Geriatrics.

The aging population and high medical costs are urgent tasks the country is facing. For Chinese AD patients, the average spending can reach 130,000 yuan (about 18,665 U.S. dollars) per year.

Lyu said the monthly cost of GV-971 is only about 3,580 yuan.

TOP STORIES
EDITOR’S CHOICE
MOST VIEWED
EXPLORE XINHUANET
010020070750000000000000011100001386782961
主站蜘蛛池模板: 91麻豆精品国产91久久久久 | 最近2018免费中文字幕4 | 国产1区2区 | 久久九九 | 人人草人人人 | 在线欧美a | www.成| 黄视频网站在线看 | 中文字幕人妻互换AV久久 | 日本一级特黄录像视频播放 | 大地资源网高清在线观看 | 91视频免费视频 | 成人国内毛片免费大战 | 国产精品国产亚洲伊人久久 | 国产福利一区二区三区在线播放 | 成年性羞羞视频免费观看无限 | 久久国产中文娱乐网 | 欧美成人毛片 | 无码喷水一区二区浪潮av | 大伊人狠狠躁夜夜躁av一区 | 久久99精品国产自在现线小黄鸭 | 亚洲喷水| 国产精品片aa在线观看 | 香港aa三级久久三级 | 青青小草AV一区二区三区 | 成A人影片免费观看日本 | 国产全黄a一级毛片91 | 国产精品亚洲一区在现观看 | 国产一区三区四区 | 国产一区在线视频播放 | 久久久久美女 | 日韩黄色av | 纯欧美一级毛片免费 | 久久综合久 | 春药玩弄少妇高潮吼叫 | 噜噜色噜噜 | 大地资源高清在线 | 种付おじさんと在线观看 | 中文字幕人成乱码熟女 | 免费一级视频在线观看 | 免费少妇A级毛片 |